Vol.

No.

February 21, 2025Feb 21, 2025

DOWNLOAD THE PDF

Cover Story

Amid funding cuts and firings, cancer groups seek relief from judges, in Congress—and in the court of public opinion

By Claire Marie Porter, Jacquelyn Cobb and Paul Goldberg

As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”

White House

“The Agency finds you are not fit…”
HHS notifications of firing add insult to injury

By Claire Marie Porter

News Analysis

Trump executive order to “Make America Healthy Again” cites questionable data from Wuhan
White House cites paper in pay-to-play journal claiming that U.S. has highest age-standardized incidence rate of cancer

By Paul Goldberg

Guest Editorial

The fight against cancer is global. Our focus must be as well.

By W. Kimryn Rathmell

Guest Editorial

As cancer research is threatened, we must engage in political advocacy

By George J. Weiner

Black History Month Conversation with The Cancer Letter Free

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

By Jacquelyn Cobb

Free Obituary

John Zaia, virologist and gene therapy pioneer, dies at 82

By Samantha Bonar and Abe Rosenberg

Podcasts

In The Headlines: What’s up with the U.S. cancer incidence rate?

In Brief

Dan Theodorescu named director of the University of Arizona Cancer Center

Charles Geyer named associate group chair of NRG Oncology

Kimberly Stegmaier appointed chair of pediatric oncology at Dana-Farber

Leon Bernal-Mizrachi appointed chair of the Department of Cancer Medicine at Wake Forest

Matthew Burow, Jessica Shank, Zachary Pursell appointed to Tulane Cancer Center leadership

Ze’ev Ronai receives NCI Outstanding Investigator Award

Jason Damsker and Michael Noonan join Fox Chase

Samuel Achilefu, Jennifer Cochran, Dorin Comaniciu elected to National Academy of Engineering

CPRIT awards $67M in research grants to Texas institutions

Clinical Roundup

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Some kidney cancer patients can safely pause treatment after two years

Opdivo + chemo improves OS in resectable lung cancer, phase III study shows

Immunotherapy + radiation show promise for bladder preservation in localized MIBC, phase II study shows

Investigational therapy shrinks drug-resistant NSCLC by activating NK cells, study finds

CAR T therapy shows durable responses in large B-cell lymphoma

Cancer cells can cooperate to survive challenging conditions, NYU scientists find

New biomarker can predict cancer aggressiveness, study finds

Scientists identify dysfunctional B cells as a new cancer immunotherapy target

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

Drugs & Targets

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 06 - February 13, 2026